The importance of PTEN deficiency in the synthetic lethality driven by PARP inhibitors has been described in several cancers (Mendes-Pereira et al. 2009; Dedes et al. 2010; McEllin et al. 2010; He et al. 2015). The gene discussed is PARP1; the disease is cancer.